Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 4
2021 6
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies.
de Joode K, van de Geer WS, van Leenders GJLH, Hamberg P, Westgeest HM, Beeker A, Oosting SF, van Rooijen JM, Beerepoot LV, Labots M, Mathijssen RHJ, Lolkema MP, Cuppen E, Sleijfer S, van de Werken HJG, van der Veldt AAM. de Joode K, et al. Sci Rep. 2023 Jul 3;13(1):10720. doi: 10.1038/s41598-023-37764-z. Sci Rep. 2023. PMID: 37400554 Free PMC article.
Remarkable Healthy Cohort of Patients With Cancer.
de Joode K, Dingemans AC, van der Veldt AAM. de Joode K, et al. J Clin Oncol. 2021 Mar 20;39(9):1092-1093. doi: 10.1200/JCO.20.03283. Epub 2021 Jan 26. J Clin Oncol. 2021. PMID: 33497269 No abstract available.
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
Basak EA, de Joode K, Uyl TJJ, van der Wal R, Schreurs MWJ, van den Berg SAA, Oomen-de Hoop E, van der Leest CH, Chaker L, Feelders RA, van der Veldt AAM, Joosse A, Koolen SLW, Aerts JGJV, Mathijssen RHJ, Bins S. Basak EA, et al. Among authors: de joode k. Biomed Pharmacother. 2022 Dec;156:113839. doi: 10.1016/j.biopha.2022.113839. Epub 2022 Oct 11. Biomed Pharmacother. 2022. PMID: 36228374 Free article.
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.
de Joode K, Tol J, Hamberg P, Cloos M, Kastelijn EA, Borgers JSW, Nuij VJAA, Klaver Y, Herder GJM, Mutsaers PGNJ, Dumoulin DW, Oomen-de Hoop E, van Diemen NGJ, Libourel EJ, Geraedts EJ, Bootsma GP, van der Leest CH, Peerdeman AL, Herbschleb KH, Visser OJ, Bloemendal HJ, van Laarhoven HWM, de Vries EGE, Hendriks LEL, Beerepoot LV, Westgeest HM, van den Berkmortel FWPJ, Haanen JBAG, Dingemans AC, van der Veldt AAM; DOCC investigators. de Joode K, et al. Eur J Cancer. 2022 Jan;160:261-272. doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25. Eur J Cancer. 2022. PMID: 34799210 Free PMC article.
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
Basak EA, Vermeer NS, de Joode K, Hurkmans DP, Velthuis DEM, Oomen-de Hoop E, Schreurs MWJ, Bins S, Koolen SLW, Debets R, van der Veldt AAM, Aerts JGJV, Joosse A, Mathijssen RHJ. Basak EA, et al. Among authors: de joode k. Eur J Cancer. 2022 Oct;174:113-120. doi: 10.1016/j.ejca.2022.07.015. Epub 2022 Aug 19. Eur J Cancer. 2022. PMID: 35988409 Free article.
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP, Sassen SDT, de Joode K, Putter L, Basak EA, Wijkhuijs AJM, Joerger M, Debets R, Koch BCP, Van der Leest CH, Schreurs MWJ, van der Veldt AAM, Aerts JGJV, Mathijssen RHJ, Koolen SLW. Hurkmans DP, et al. Among authors: de joode k. J Immunother Cancer. 2021 Jun;9(6):e002344. doi: 10.1136/jitc-2021-002344. J Immunother Cancer. 2021. PMID: 34088739 Free PMC article.
19 results